glp 1 cardiovascular disease Effects of Glucagon-Like Peptide-1 Receptor Agonists GLP1-receptor Agonists for Obesity-associated Cardiovascular

Front Immunol (2020) 11:906

doi: 10.2147/DMSO.S215789

With regard to RECOVER, this is apparently because trials funded by NIH must use doses that have an established toxicology and pharmacokinetic profile already accepted by FDA

NICE recommends semaglutide 2.4mg (Wegovy) for a maximum of 2 years on the NHS within specialist weight management services

The most widely reported improvement with microdosing this medication is in reducing inflammation

Michael White, professor of pharmacy practice at the University of Connecticut School of Pharmacy, is skeptical, to say the least: The marketing seems to suggest that you could get with these natural products, these natural ingredients, the same effect that you can get with GLP-1 agonists, which is simply not the case